Overview

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
Phase:
Phase 2
Details
Lead Sponsor:
Agennix
Treatments:
Lactoferrin
Talactoferrin alfa